GlassScriptPhysician profile
Adam S Greenberg
NPI 1932193729
$4,549.62
in general payments reported to CMS, 2019-2025
28 companies · $865 in 2025
The $865 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $465 · 2021: $686 · 2022: $531 · 2023: $622 · 2024: $1,008 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $664.68 | 2020-2025 | Ilumya |
| Merz North America, INC. | $421.58 | 2020-2021 | |
| Abbvie INC. | $385.35 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $324.18 | 2021-2025 | |
| Galderma Laboratories, L.P. | $243.81 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $237.37 | 2022-2025 | Libtayo, Dupixent |
| Incyte Corporation | $218.15 | 2021-2025 | Opzelura |
| Genzyme Corporation | $214.91 | 2022-2025 | |
| Organogenesis INC. | $193.33 | 2021-2025 | Simplimax, Puraply, Novachor |
| Convatec INC. | $151.21 | 2024-2025 | |
| Leo Pharma INC. | $150.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.51 | 2022-2025 | Spevigo |
| Ucb, INC. | $131.41 | 2021-2025 | Bimzelx |
| Biofrontera INC. | $124.05 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Amgen INC. | $122.22 | 2020-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120.55 | 2021-2022 | |
| Elekta, INC. | $105.11 | 2024-2025 | Elekta Medical Linear Accelerator, Flexitron Hdr |
| E.R. Squibb & Sons, L.L.C. | $89.29 | 2023-2025 | Sotyktu |
| Almirall LLC | $85.90 | 2021-2025 | Seysara |
| Strata Skin Sciences, INC. | $63.66 | 2024-2025 | Xtrac |
| Allergan, INC. | $59.57 | 2021-2022 | |
| Pfizer INC. | $58.11 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $51.69 | 2020 | |
| Genentech USA, INC. | $50.20 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.74 | 2019 | |
| Janssen Biotech, INC. | $44.83 | 2020-2021 | |
| Celgene Corporation | $32.18 | 2019 | |
| Kerecis Limited | $25.30 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.